Who are Vyzulta's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Travatan, Xalatan, Hemabate, Enzaprost, Fluoprostenol, Xalatan.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/latanoprostene-bunod.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Vyzulta — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vyzulta (LATANOPROSTENE BUNOD) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Cardiovascular.

marketed Prostaglandin F2-alpha receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Vyzulta (LATANOPROSTENE BUNOD) — Bausch Health. Vyzulta works by activating the Prostaglandin F2-alpha receptor, which increases the outflow of aqueous humor from the eye, thereby reducing intraocular pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vyzulta TARGET	LATANOPROSTENE BUNOD	Bausch Health	marketed		Prostaglandin F2-alpha receptor	2017-01-01
Travatan	TRAVOPROST		marketed	Prostaglandin Analog [EPC]	Prostaglandin F2-alpha receptor	2001-01-01
Xalatan	LATANOPROST	Thea Pharma	marketed	Prostaglandin Analog [EPC]	Prostaglandin F2-alpha receptor	1996-01-01
Hemabate	CARBOPROST	Pfizer	marketed	Prostaglandin Analog	Prostaglandin F2-alpha receptor	1979-01-01
Enzaprost	DINOPROST	Pfizer	marketed	dinoprost	Prostaglandin F2-alpha receptor	1976-01-01
Fluoprostenol	FLUPROSTENOL		marketed		Prostaglandin E2 receptor EP3 subtype, Prostaglandin F2-alpha receptor
Xalatan	Xalatan	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	marketed		Prostaglandin E2 receptor EP1 subtype, Prostaglandin E2 receptor EP3 subtype, Prostaglandin F2-alpha receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vyzulta — Competitive Intelligence Brief. https://druglandscape.com/ci/latanoprostene-bunod. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab